John Cavanagh
Overview
Explore the profile of John Cavanagh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
881
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Milton M, Allen C, Feldmann E, Bobay B, Jung D, Stephens M, et al.
Mol Microbiol
. 2017 Jul;
106(2):223-235.
PMID: 28755524
With antibiotic resistance increasing at alarming rates, targets for new antimicrobial therapies must be identified. A particularly promising target is the bacterial two-component system. Two-component systems allow bacteria to detect,...
12.
Draughn G, Allen C, Routh P, Stone M, Kirker K, Boegli L, et al.
Drug Des Devel Ther
. 2017 Feb;
11:153-162.
PMID: 28138218
2-Aminoimidazole (2-AI)-based compounds have been shown to efficiently disrupt biofilm formation, disperse existing biofilms, and resensitize numerous multidrug-resistant bacteria to antibiotics. Using and , we provide initial pharmacological studies regarding...
13.
Stephens M, Hubble V, Ernst R, van Hoek M, Melander R, Cavanagh J, et al.
Medchemcomm
. 2016 Feb;
7(1):128-131.
PMID: 26877862
A screen of 20 compounds identified small molecule adjuvants capable of potentiating anitbiotic activty against . Analogue synthesis of an initial hit compound led to the discovery of a potentially...
14.
15.
Wahome P, Beauchesne K, Pedone A, Cavanagh J, Melander C, Zimba P, et al.
Mar Drugs
. 2014 Dec;
13(1):65-75.
PMID: 25548974
Aquatic microbes produce diverse secondary metabolites with interesting biological activities. Cytotoxic metabolites have the potential to become lead compounds or drugs for cancer treatment. Many cytotoxic compounds, however, show undesirable...
16.
Stowe S, Thompson R, Peng L, Su Z, Blackledge M, Draughn G, et al.
Curr Drug Deliv
. 2014 Oct;
12(2):223-30.
PMID: 25348099
Acinetobacter baumannii has quickly become one of the most insidious and prevalent nosocomial infections. Recently, the reverse-amide class of 2-aminoimidazole compounds (RA-2AI) was found both to prevent A. baumannii biofilm...
17.
Olson A, Tucker A, Bobay B, Soderblom E, Moseley M, Thompson R, et al.
Structure
. 2014 Oct;
22(11):1650-6.
PMID: 25308864
The AbrB protein from Bacillus subtilis is a DNA-binding global regulator controlling the onset of a vast array of protective functions under stressful conditions. Such functions include biofilm formation, antibiotic...
18.
Brackett C, Melander R, An I, Krishnamurthy A, Thompson R, Cavanagh J, et al.
J Med Chem
. 2014 Aug;
57(17):7450-8.
PMID: 25137478
Recent efforts toward combating antibiotic resistance in bacteria have focused on Gram-positive bacteria; however, multidrug-resistant Gram-negative bacteria pose a significant risk to public health. An orthogonal approach to the development...
19.
Tucker A, Bobay B, Banse A, Olson A, Soderblom E, Moseley M, et al.
J Mol Biol
. 2014 Feb;
426(9):1911-24.
PMID: 24534728
Bacteria respond to adverse environmental conditions by switching on the expression of large numbers of genes that enable them to adapt to unfavorable circumstances. In Bacillus subtilis, many adaptive genes...
20.
Bobay B, Hoch J, Cavanagh J
Biomol Concepts
. 2014 Feb;
3(2):175-182.
PMID: 24494032
Two-component signal transduction systems of microbes are a primary means to respond to signals emanating from environmental and metabolic fluctuations as well as to signals coordinating the cell cycle with...